| abstract |
The objective of the present invention is to provide a novel compound that inhibits at least one type selected from the group consisting of TLR3, TLR7 and TLR9, and that has excellent preventive and therapeutic effects on autoimmune diseases, inflammations, allergies, etc. A compound represented by general formula (1) or a salt thereof, or a solvate thereof. [In the formula: rings W and Z are 5 to 7 membered saturated or partially unsaturated nitrogen-containing heterocyclic groups; T is a C 1-6 alkyl group which may be substituted with an oxo group; ring Y is a group represented by formulas (2), (3) or (4);n(2) (3) (4)nX 1 , X 2 and X 3 are C-R 7 or nitrogen atoms, wherein X 1 and X 2 are not simultaneously C-R 7 ; R 7 is a hydrogen atom, a halogen atom, a hydroxyl group, etc.; S and U are single bonds or N-R 8 ; R 8 is a hydrogen atom or a C 1-6 alkyl group; V is a hydrogen atom, a C 1-6 alkyl group, a C 6-10 aryl C 1-3 alkyl group, a 3 to 7 membered saturated heterocyclic group, etc.] |